 DURHAM, NC ACCESSWIRE June 22, 2020 Heat Biologics, Inc. Heat HTBX, a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, including multiple oncology product candidates and a novel COVID-19 vaccine, today announced that the first patient has been treated in the Companys first-in-human Phase 1 clinical trial evaluating PTX-35, the first antibody product candidate developed by Heat Biologics Pelican Therapeutics subsidiary. This trial is supported by a 15.2 million grant from the Cancer Prevention and Research Institute of Texas CPRIT. 